1. Elastic compression stockings to prevent post-thrombotic syndrome in proximal deep venous thrombosis patients without thrombus removal
- Author
-
Ruihua Wang, Xinrui Yang, Kaichuang Ye, Minyi Yin, Xing Zhang, and Xinwu Lu
- Subjects
Adult ,Male ,China ,medicine.medical_specialty ,Time Factors ,Risk Assessment ,Postthrombotic Syndrome ,law.invention ,Randomized controlled trial ,Risk Factors ,law ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Thrombus ,Adverse effect ,Aged ,Venous Thrombosis ,business.industry ,Incidence ,Middle Aged ,medicine.disease ,Confidence interval ,Surgery ,Venous thrombosis ,Treatment Outcome ,Relative risk ,Female ,Cardiology and Cardiovascular Medicine ,business ,Stockings, Compression ,Post-thrombotic syndrome - Abstract
To evaluate the effectiveness of elastic compression stockings (ECS) in prevention of post-thrombotic syndrome (PTS) in patients suffering from proximal deep venous thrombosis (DVT) who did not undergo thrombus removal procedures.In this randomized trial, patients with Iliofemoral venous thrombosis (IFDVT) and femoral-popliteal venous thrombosis who had not undergone thrombus removal procedures were screened at a single medical institution between December 2016 and June 2018. These patients were randomly assigned as an ECS group (wear ECS) and control group (not wear ECS). The primary end point was the incidence of PTS based on the Villalta scale at 24 months. The secondary end points included patient quality of life and symptom severity based on the VEINES-QoL/Sym questionnaire. Recurrent DVT in the same limb, compliance with ECS use, and other adverse events were also recorded. A logistic regression analysis was also performed to determine risk factors of PTS.Two hundred thirty-two patients were included in this study. One hundred thirteen patients were in the ECS group and 119 in the control group. The incidence of PTS was 42.0% in the ECS group and 57.8% in the control group at 24 months (risk ratio [RR], 0.726; 95% confidence interval [CI] 0.547-0.964; P = .024). The VEINES-QoL score was 63.7 ± 4.6 in the ECS group, which was higher than in the control group (60.6 ± 6.9; P .001). Moreover, the VEINES-Sym scores revealed that patients in the ECS group reported better symptom relief than those in the control group (45.8 ± 5.1 vs 43.8 ± 6.1; P = .014). According to Logistic regression analysis of the entire cohort, IFDVT was a risk factor for PTS (RR, 2.253; 95% CI, 1.136-4.468) and high compliance with the use of ECS was protect factor (RR, 0.516; 95% CI, 0.277-0.961).These results suggest that ECS can prevent PTS in patients with IFDVT and femoral popliteal venous thrombosis who do not undergo thrombus removal procedures.
- Published
- 2022